What is the difference between Erdafitinib and Erlotinib?

厄达替尼（Erdafitinib）和厄洛替尼（Erlotinib）是两种用于癌症治疗的药物，它们在药理学、作用机制、临床应用等方面存在显著的区别。以下是对这两种药物的详细比较，涵盖了它们的结构、作用机制、适应症、不良反应等方面。

1. Structural differences

厄达替尼（Erdafitinib）：厄达替尼是一种口服的小分子酪氨酸激酶抑制剂，属于第一代 FGFR（fibroblast growth factor receptor，纤维母细胞生长因子受体）抑制剂。 Its chemical structure is designed to inhibit abnormally activated FGFR, thereby inhibiting the growth of cancer cells.

厄洛替尼（Erlotinib）：厄洛替尼是一种口服的小分子表皮生长因子受体（EGFR）酪氨酸激酶抑制剂，属于第一代 EGFR 抑制剂。它通过抑制 EGFR 的活性，阻断了癌细胞的增殖和生长。

2. Mechanism of action

厄达替尼：厄达替尼主要作用于 FGFR，该受体在多种癌症中表达异常。 By inhibiting FGFR activation, erdafitinib blocks the growth and spread of cancer cells. FGFR 通常在尿路上皮癌等癌症中表达异常，厄达替尼被用于治疗这些特定类型的癌症。

厄洛替尼：厄洛替尼主要作用于 EGFR，这是一种位于细胞表面的受体，参与了癌细胞的增殖和存活。通过抑制 EGFR，厄洛替尼阻断了细胞信号传导通路，从而抑制了癌细胞的生长。

3. Clinical Application

Erdafitinib: Erdafitinib is used primarily to treat advanced or metastatic urothelial carcinoma, a type of cancer characterized by abnormal activation of the FGFR gene. The approval of erdafitinib was primarily based on test results of patients' genetic mutation status.

Erlotinib: Erlotinib is mainly used for the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. It is often used as first-line treatment for certain patients with EGFR mutation-positive NSCLC . In addition, erlotinib is also used to treat advanced or metastatic pancreatic cancer.

4. Adverse reactions

Erdafitinib: Common adverse reactions of erdafitinib include hypertension, fatigue, hand-foot syndrome (hand-foot skin reaction), proteinuria, etc. It is important to monitor the patient's blood pressure and liver function while taking erdafitinib.

Erlotinib: Common adverse reactions of erlotinib include rash, diarrhea, fatigue, infection, etc. In addition, because EGFR is also expressed in normal skin and intestines, erlotinib may cause skin and gastrointestinal discomfort.

5. Drug resistance

Erdafitinib: Some patients may develop resistance to erdafitinib, which may be related to mutations in the FGFR gene. During the treatment process, the patient's genetic mutation status needs to be regularly monitored so that the treatment plan can be adjusted in a timely manner.

Erlotinib: Some patients may develop resistance to erlotinib after a period of use, which may involve mutations in the EGFR gene. In this case, doctors may need to consider switching treatment strategies, such as using other targeted therapies or chemotherapy.

Overall, erdafitinib and erlotinib are two different classes of anticancer drugs, each used to treat specific types of cancer. The choice of which drug to use often depends on the patient's cancer type, genetic mutation status, and the individual's health. When using these drugs, clinicians should develop individualized treatment plans based on the patient's specific conditions and closely monitor the patient's responses and adverse reactions so that treatment can be adjusted in a timely manner.

Erdafitinib is not currently on the market in China, so patients cannot purchase it domestically and need to purchase erdafitinib through foreign channels. The original drug of erdafitinib is mainly the Hong Kong version of the original drug, with a price of more than 20,000, and needs to be purchased through a Hong Kong pharmacy. The generic drugs are relatively cheaper, mainly the Laos version and the Bangladesh Yaopin International version, with a price of about 1,000 to 2,000, and the ingredients of the original drug and the generic drug are basically the same.